AptaBio Therapeutics saw no growth in patent filings in April and highest growth of 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of AptaBio Therapeutics’s patent filings and grants. Buy the databook here.
Smarter leaders trust GlobalData
AptaBio Therapeutics has been focused on protecting inventions in European Patent Office(EPO) with two publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent grants with nearly 50% of grants. The European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where AptaBio Therapeutics is filings its patents. Among the top granted patent authorities, AptaBio Therapeutics has 50% of its grants in European Patent Office(EPO) and 50% in United States(US).
Gilead Sciences could be the strongest competitor for AptaBio Therapeutics
Liver diseases related patents lead AptaBio Therapeutics portfolio followed by liver fibrosis, and fibrosis
AptaBio Therapeutics has highest number of patents in liver diseases followed by liver fibrosis, fibrosis, inflammation, and ageing.
For comprehensive analysis of AptaBio Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.
Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.
